Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.30 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.30 |
| ▸ | STK4 | Q13043 | 1/20 | 0.30 |
| ▸ | STK3 | Q13188 | 1/20 | 0.30 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.30 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.30 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | MAP3K3 | Q99759 | 1/20 | 0.30 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.30 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.30 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.30 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147293 | 0.84 | ALDH1A1 (0.37) | — | |
| SCHEMBL2980754 | 0.82 | — | — | |
| SCHEMBL2986295 | 0.82 | CDK2 (0.35) | ABL1 | |
| SCHEMBL2981732 | 0.81 | — | — | |
| SCHEMBL2980598 | 0.80 | — | — | |
| SCHEMBL2977647 | 0.78 | — | — | |
| SCHEMBL2974888 | 0.78 | — | — | |
| SCHEMBL2975235 | 0.78 | MERTK (0.34) | PIP5K1CPIK3CAPIK3CG | |
| SCHEMBL3071448 | 0.78 | CDK2 (0.35) | ABL1 | |
| SCHEMBL27688635 | 0.78 | QPCT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | AURKA 71/4885DCLK1 464/4885PIP5K1C 190/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | AURKA 71/4885DCLK1 464/4885PIP5K1C 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.